Crossley George, Boyle Andrew, Vitense Holly, Sherfesee Lou, Mead R Hardwin
St. Thomas Research Institute, Nashville, TN 37203, USA.
Am Heart J. 2008 Nov;156(5):840-6. doi: 10.1016/j.ahj.2008.06.028. Epub 2008 Sep 11.
Indications for implantable cardioverter defibrillators (ICDs) and cardiac resynchronization therapy defibrillators have greatly expanded in the last 5 years, encompassing a wider variety of patients with a multitude of comorbidities. To meet the needs of these patients, the managing clinicians need to streamline their follow-up care. New ICD/cardiac resynchronization therapy defibrillators provide enhanced device status and disease progression remote monitoring capabilities that support more comprehensive and efficient follow-ups. In addition, this monitoring between follow-ups is likely to impact health care utilization.
The Clinical evaluation Of remote NotificatioN to rEduCe Time to clinical decision (CONNECT) study will randomize approximately 2,000 patients implanted with an ICD with or without CRT capabilities from 150 sites in the United States to remote monitoring versus standard in-office care. This study will evaluate the time from clinical event to clinical decision in response to the event, as well as the associated impact on health care utilization and quality of life. Patients monitored remotely will be provided a home monitor for transmitting device diagnostics to the clinician's office. These devices will use wireless telemetry, allowing the automatic transmission of diagnostics to the office without the need for patient intervention. Patients receiving in-office care will be followed in the office at a fixed schedule and without remote monitoring. All patients will be followed for 15 months postimplant.
The CONNECT study is evaluating the impact of remote monitoring and early notification using wireless telemetry on the time to clinical decisions, the allocation of health care utilization, and quality of life. Results from this study are expected mid-2009.
在过去5年中,植入式心脏复律除颤器(ICD)和心脏再同步治疗除颤器的适应症有了极大扩展,涵盖了更多患有多种合并症的患者。为满足这些患者的需求,临床管理人员需要简化他们的随访护理。新型ICD/心脏再同步治疗除颤器提供了增强的设备状态和疾病进展远程监测功能,支持更全面、高效的随访。此外,随访期间的这种监测可能会影响医疗保健的利用。
临床评估远程通知以缩短临床决策时间(CONNECT)研究将把来自美国150个地点的约2000名植入有或没有心脏再同步治疗功能的ICD的患者随机分为远程监测组和标准门诊护理组。本研究将评估从临床事件发生到针对该事件做出临床决策的时间,以及对医疗保健利用和生活质量的相关影响。接受远程监测的患者将获得一个家用监测器,用于将设备诊断信息传输到临床医生办公室。这些设备将使用无线遥测技术,无需患者干预即可自动将诊断信息传输到办公室。接受门诊护理的患者将按固定时间表在门诊接受随访,不进行远程监测。所有患者将在植入后随访15个月。
CONNECT研究正在评估使用无线遥测技术进行远程监测和早期通知对临床决策时间、医疗保健利用分配和生活质量的影响。该研究结果预计在2009年年中得出。